ClinicalTrials.gg
CompletedNCT06285240Updated Oct 14, 2025Results posted

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

A Phase 1 interventional study of MK-1167 and Donepezil in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Enrollment
18th of 29
28 · median 34
Started
2024
with 2 others
Phase 1
18 of 31
none open now
Registered
28th of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 in phase 1, and was the 28th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reports a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before Screening, that is either corroborated by an informant who knows the subject well or is documented in medical records
  • Meets the criteria for a diagnosis of probable Alzheimer's disease (AD) based on the National Institute of Neurological and Communicative Disorders - Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD
  • Is receiving donepezil 10 mg daily for symptomatic treatment of cognitive impairment associated with AD. The dose level must be stable for at least 2 months prior to Screening. If receiving donepezil via a transdermal system (ie, patch), it should be a 10-mg/day dose and should switch prescription to a 10-mg oral daily dose, before enrollment
  • Has a reliable and competent trial partner/caregiver who has a close relationship with the participant, has face-to-face contact at least 3 days a week for a minimum of 6 waking hours a week, and is willing to accompany the participant, if desired, to study visits

Exclusion criteria

Exclusion Criteria:

  • History of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases that are not under medical control over the past 2 months.
  • Has evidence of a clinically relevant or unstable psychiatric disorder, based on criteria, or has a history of clinically significant psychiatric disorder in the last 5 years. Generalized anxiety disorder, and/or insomnia under good control for ≥ 2 months on stable medical therapy may not be exclusionary.
  • History of cancer (). Participants with adequately treated disease deemed as "cured," or who, in the opinion of the study investigator, are highly unlikely to sustain a recurrence for the duration of the study, may be enrolled at the discretion of the investigator and Sponsor.
  • History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or nonprescription drugs or food.
  • Had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study, until the poststudy visit. There may be certain protocol-specified medications that are permitted.
  • The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 3 months of screening.
  • Consumes greater than 3 servings of alcoholic beverages per day. Participants who consume 4 servings of alcoholic beverages per day may be enrolled at the discretion of the investigator.
  • The participant is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Panel A: MK-1167 + Donepezil 10mg QD

    Participants receive 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10mg oral Donepezil on Days -3 to 21.

    Drug: MK-1167 · Drug: Donepezil

  • Placebo comparator
    Panel A: Placebo to MK-1167 + Donepezil 10mg QD

    Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10mg oral Donepezil QD on Days -3 to 21.

    Drug: Donepezil · Drug: Placebo

  • Experimental
    Panel B: MK-1167 6mg QD + Donepezil 10mg QD

    Participants receive 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.

    Drug: MK-1167 · Drug: Donepezil

  • Placebo comparator
    Panel B: Placebo to MK-1167 + Donepezil 10mg QD

    Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also receive 10mg oral Donepezil QD on Days -3 to 31.

    Drug: Donepezil · Drug: Placebo

Interventions

  • 1 mg and 5 mg oral capsules

  • 10 mg oral tablets

  • DrugPlacebo

    MK-1167 matching placebo administered oral capsules

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

    Time frame: Up to approximately 7 weeks

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.

    Time frame: Up to approximately 4 weeks

Secondary outcomes

  1. Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167

    AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167.

    Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  2. Panel A: AUC0-24 After Administration of 3mg of MK-1167

    AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  3. Panel B: AUC0-24 After Administration of 6mg of MK-1167

    AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  4. Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167

    Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167.

    Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  5. Panel A: Cmax After Administration of 3mg of MK-1167

    Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  6. Panel B: Cmax After Administration of 6mg of MK-1167

    Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  7. Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167

    C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167.

    Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  8. Panel A: C24 After Administration of 3mg of MK-1167

    C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  9. Panel B: C24 After Administration of 6mg of MK-1167

    C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  10. Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167

    Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167.

    Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  11. Panel A: Tmax After Administration of 3mg of MK-1167

    Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  12. Panel B: Tmax After Administration of 6mg of MK-1167

    Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  13. Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167

    CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  14. Panel B: CL/F After Administration of 6mg of MK-1167

    CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  15. Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167

    t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  16. Panel B: t1/2 After Administration of 6mg of MK-1167

    t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  17. Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167

    Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167.

    Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  18. Panel B: Vz/F After Administration of 6mg of MK-1167

    Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167.

    Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

  19. Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24.

    Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  20. Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24.

    Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  21. Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax.

    Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  22. Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax.

    Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  23. Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24.

    Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  24. Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

    Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24.

    Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

07

Results

Posted Oct 14, 2025

Participant flow

Participant flow — Overall Study
MilestonePanel A: MK-1167 + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QD
Started12493
Treated12493
Panel a participants who received 6mg of mk-116712000
Panel a participants who received 3mg of mk-116712000
Completed10483
Not completed2010
Withdrew: Withdrawal by subject2000
Withdrew: Serious adverse event0010

Outcome measures

SecondaryPanel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167.

Time frame:
Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μM*hour
Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167
μM*hourPanel A: MK-1167 6mg QD + Donepezil 10mg QD
Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-11672.17 (1.22 to 3.84)
SecondaryPanel A: AUC0-24 After Administration of 3mg of MK-1167

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μM*hour
Panel A: AUC0-24 After Administration of 3mg of MK-1167
μM*hourPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Day 88.70 (4.95 to 15.3)
Day 218.08 (4.56 to 14.3)
SecondaryPanel B: AUC0-24 After Administration of 6mg of MK-1167

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μM*hour
Panel B: AUC0-24 After Administration of 6mg of MK-1167
μM*hourPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Day 12.48 (2.04 to 3.01)
Day 2322.2 (18.1 to 27.1)
Day 3122.9 (18.8 to 28.0)
SecondaryPanel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167.

Time frame:
Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167
μmol/LiterPanel A: MK-1167 6mg QD + Donepezil 10mg QD
Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-11670.129 (0.0731 to 0.228)
SecondaryPanel A: Cmax After Administration of 3mg of MK-1167

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel A: Cmax After Administration of 3mg of MK-1167
μmol/LiterPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Day 80.434 (0.247 to 0.761)
Day 210.413 (0.234 to 0.729)
SecondaryPanel B: Cmax After Administration of 6mg of MK-1167

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel B: Cmax After Administration of 6mg of MK-1167
μmol/LiterPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Day 10.145 (0.121 to 0.174)
Day 231.11 (0.919 to 1.35)
Day 311.14 (0.941 to 1.38)
SecondaryPanel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167.

Time frame:
Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167
μmol/LiterPanel A: MK-1167 6mg QD + Donepezil 10mg QD
Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-11670.0902 (0.0500 to 0.163)
SecondaryPanel A: C24 After Administration of 3mg of MK-1167

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel A: C24 After Administration of 3mg of MK-1167
μmol/LiterPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Day 80.362 (0.203 to 0.647)
Day 210.313 (0.174 to 0.565)
SecondaryPanel B: C24 After Administration of 6mg of MK-1167

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · μmol/Liter
Panel B: C24 After Administration of 6mg of MK-1167
μmol/LiterPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Day 10.0917 (0.0731 to 0.115)
Day 230.729 (0.576 to 0.922)
Day 310.875 (0.691 to 1.11)
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

Time frame:
Up to approximately 7 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPanel A: MK-1167 6mg QD + Donepezil 10mg QDPanel A: MK-1167 3mg QD + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD+ Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QD
Number of Participants Who Experienced an Adverse Event (AE)35260
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.

Time frame:
Up to approximately 4 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPanel A: MK-1167 6mg QD + Donepezil 10mg QDPanel A: MK-1167 3mg QD + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QD
Number of Participants Who Discontinued Study Treatment Due to an AE00010
SecondaryPanel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167.

Time frame:
Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Median · hours
Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167
hoursPanel A: MK-1167 6mg QD + Donepezil 10mg QD
Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-11671.54 (0.50 to 8.00)
SecondaryPanel A: Tmax After Administration of 3mg of MK-1167

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Median · hours
Panel A: Tmax After Administration of 3mg of MK-1167
hoursPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Day 86.00 (0.00 to 23.97)
Day 214.01 (1.22 to 11.92)
SecondaryPanel B: Tmax After Administration of 6mg of MK-1167

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Median · hours
Panel B: Tmax After Administration of 6mg of MK-1167
hoursPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Day 11.08 (0.48 to 5.78)
Day 234.03 (0.58 to 11.92)
Day 312.97 (0.42 to 11.90)
SecondaryPanel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167

CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · Liter/hour
Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167
Liter/hourPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-11670.879 ± 166.9
SecondaryPanel B: CL/F After Administration of 6mg of MK-1167

CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · Liter/hour
Panel B: CL/F After Administration of 6mg of MK-1167
Liter/hourPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: CL/F After Administration of 6mg of MK-11670.606 ± 32.3
SecondaryPanel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167

t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · hours
Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167
hoursPanel A: MK-1167 3 mg QD + Donepezil 10mg QD
Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167194 ± 48.2
SecondaryPanel B: t1/2 After Administration of 6mg of MK-1167

t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · hour
Panel B: t1/2 After Administration of 6mg of MK-1167
hourPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: t1/2 After Administration of 6mg of MK-1167193 ± 40.4
SecondaryPanel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167

Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167.

Time frame:
Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · Liter
Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167
LiterPanel A: MK-1167 3mg QD + Donepezil 10mg QD
Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167246 ± 166.6
SecondaryPanel B: Vz/F After Administration of 6mg of MK-1167

Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167.

Time frame:
Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Reported as:
Geometric mean · Liter
Panel B: Vz/F After Administration of 6mg of MK-1167
LiterPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Vz/F After Administration of 6mg of MK-1167169 ± 19.7
SecondaryPanel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24.

Time frame:
Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-11678.95 (7.80 to 10.27)
SecondaryPanel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24.

Time frame:
Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-11679.26 (8.08 to 10.62)
SecondaryPanel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax.

Time frame:
Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-11677.69 (6.46 to 9.16)
SecondaryPanel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax.

Time frame:
Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-11677.88 (6.62 to 9.38)
SecondaryPanel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24.

Time frame:
Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-11677.94 (6.64 to 9.50)
SecondaryPanel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24.

Time frame:
Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167
RatioPanel B: MK-1167 6mg QD + Donepezil 10mg QD
Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-11679.54 (7.97 to 11.40)

Adverse events

Collected over Up to approximately 25 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: MK-1167 6mg QD + Donepezil 10mg QD0/12 (0%)0/12 (0%)3/12 (25%)
Panel A: MK-1167 3mg QD + Donepezil 10mg QD0/12 (0%)0/12 (0%)5/12 (41.7%)
Panel A: Placebo to MK-1167 + Donepezil 10mg QD0/4 (0%)0/4 (0%)2/4 (50%)
Panel B: MK-1167 6mg QD + Donepezil 10mg QD0/9 (0%)1/9 (11.1%)6/9 (66.7%)
Panel B: Placebo to MK-1167 + Donepezil 10mg QD0/3 (0%)0/3 (0%)0/3 (0%)
Most frequent serious events
Most frequent serious events
EventPanel A: MK-1167 6mg QD + Donepezil 10mg QDPanel A: MK-1167 3mg QD + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QD
Deep vein thrombosisVascular disorders0/120/120/41/90/3
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPanel A: MK-1167 6mg QD + Donepezil 10mg QDPanel A: MK-1167 3mg QD + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QD
DizzinessNervous system disorders0/120/121/41/90/3
IrritabilityPsychiatric disorders0/120/121/40/90/3
HyperhidrosisSkin and subcutaneous tissue disorders0/120/121/40/90/3
Orthostatic hypotensionVascular disorders0/120/121/40/90/3
PallorVascular disorders0/120/121/40/90/3
Upper respiratory tract infectionInfections and infestations0/120/120/42/90/3
DiarrhoeaGastrointestinal disorders2/120/120/40/90/3
Ear painEar and labyrinth disorders0/120/120/41/90/3
ConstipationGastrointestinal disorders0/120/120/41/90/3
NauseaGastrointestinal disorders0/120/120/41/90/3

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(Years)Panel A: MK-1167 + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QDTotal
Mean68.2 ± 8.263.5 ± 8.769.9 ± 8.675.3 ± 2.968.8 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-1167 + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QDTotal
Female633113
Male616215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: MK-1167 + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QDTotal
Hispanic or Latino424212
Not Hispanic or Latino825116
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: MK-1167 + Donepezil 10mg QDPanel A: Placebo to MK-1167 + Donepezil 10mg QDPanel B: MK-1167 6mg QD + Donepezil 10mg QDPanel B: Placebo to MK-1167 + Donepezil 10mg QDTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American623011
White626317
More than one race00000
Unknown or Not Reported00000
08

Study locations

3 sites
  • Velocity Clinical Research, Hallandale Beach ( Site 0001)
    Hallandale, Florida 33009, United States
  • CenExel iResearch, LLC ( Site 0003)
    Decatur, Georgia 30030, United States
  • CenExel iResearch, LLC ( Site 0004)
    Savannah, Georgia 31405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Sep 2024, 5 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 5 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Mar 28, 2024
Primary completionActual
Sep 23, 2024
CompletionActual
Sep 23, 2024
Results first posted
Oct 14, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06285240
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 28, 2024
Primary completion
Sep 23, 2024
Completion
Sep 23, 2024
Results posted
Oct 14, 2025
Last update
Oct 14, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1167

Start the discussion